Clin Exp Otorhinolaryngol.  2010 Mar;3(1):42-47.

XPD Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck in a Korean Sample

• Ji YB
• Tae K
• Lee YS
• Lee SH
• Kim KR
• Park CW
• Park BL
• Shin HD

Abstract

OBJECTIVES
XPD is a major player in nucleotide excision repair, which is one of the basic pathways of DNA repair. The objective of this study was to investigate the association of XPD single nucleotide polymorphisms (SNPs) and the risk of squamous cell carcinoma of the head and neck (SCCHN) in Koreans.
METHODS
We performed XPD +23591G>A and +35931A>C genotyping in 290 SCCHN patients and 358 controls.
RESULTS
The frequencies of the XPD +23591G>A (GG/GA/AA) genotypes were 89.0%/11.0%/0% in the patients and 90.3%/8.8%/0.9% in the controls, respectively. The odds ratio (OR) of the XPD +23591 GA genotype was 1.94 (0.92 to 4.08) in reference to the GG genotype. The frequencies of the XPD +35931A>C (AA/AC/CC) genotypes were 86.9%/12.0%/1.1% in the patients and 85.6%/13.8%/0.6% in the controls, respectively. The OR of the XPD +35931 AC and CC genotypes were 0.98 (0.51 to 1.88) and 2.68 (0.71 to 10.1), respectively, in reference to the AA genotype. On the subgroup analyses according to the smoking and drinking statuses, the SNPs and haplotypes of XPD showed no statistically significant association with the risk of SCCHN.
CONCLUSION
The results of this study suggest that the XPD +23591G>A and +35931A>C SNPs are not associated with the risk of SCCHN in Koreans; however, a further study with a larger number of subjects is necessary to verify this conclusion.

Keyword

Polymorphism; XPD; Head and neck cancer; Squamous cell carcinoma

MeSH Terms

Carcinoma, Squamous Cell
DNA Repair
Drinking
Genotype
Haplotypes
Head
Head and Neck Neoplasms
Humans
Neck
Odds Ratio
Polymorphism, Single Nucleotide
Smoke
Smoking
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Smoke

Reference

1. National Central Cancer Center Registry. 2001 Annual report of the Korea Central Cancer Registry. 2003. Goyang: National Cancer Center.

2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1998; Jan–Feb. 48(1):6–29. PMID: 9449931.

3. Yang M, Kim WH, Choi Y, Lee SH, Kim KR, Lee HS, et al. Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur J Cancer Prev. 2006; 6. 15(3):269–273. PMID: 16679872.

4. Yang M, Kang MJ, Choi Y, Kim CS, Lee SM, Park CW, et al. Associations between XPC expression, genotype, and the risk of head and neck cancer. Environ Mol Mutagen. 2005; 5. 45(4):374–379. PMID: 15657918.

5. Tae K, Lee HS, Park BJ, Park CW, Kim KR, Cho HY, et al. Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population. Int J Cancer. 2004; 9. 20. 111(5):805–808. PMID: 15252855.

6. Shin CS, Ahn KS, Tae K, Lee HS, Kim HJ, Kong G. Genetic susceptibilities of cytochrome P4501A1 and glutathione S-transferase M1 to the risk for Korean head and neck squamous cell carcinoma patients. Korean J Otolaryngol - Head Neck Surg. 1999; 2. 42(2):202–208.

7. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ. 1996; 9. 21. 313(7059):716–721. PMID: 8819440.

8. Schantz SP, Byers RM, Goepfert H, Shallenberger RC, Beddingfield N. The implication of tobacco use in the young adult with head and neck cancer. Cancer. 1988; 10. 01. 62(7):1374–1380. PMID: 3416276.

9. Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett. 2002; 9. 26. 183(2):123–130. PMID: 12065086.

10. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001; 5. 17. 411(6835):366–374. PMID: 11357144.

11. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev. 2001; 1. 01. 15(1):15–23. PMID: 11156600.

12. Evans E, Moggs JG, Hwang JR, Egly JM, Wood RD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J. 1997; 11. 03. 16(21):6559–6573. PMID: 9351836.

13. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002; 12. 11(12):1513–1530. PMID: 12496039.

14. Sturgis EM, Zheng R, Li L, Castillo EJ, Eicher SA, Chen M, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis. 2000; 12. 21(12):2219–2223. PMID: 11133811.

15. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2002; 9. 128(9):1084–1088. PMID: 12220217.

16. Buch S, Zhu B, Davis AG, Odom D, Siegfried JM, Grandis JR, et al. Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract. Mol Carcinog. 2005; 4. 42(4):222–228. PMID: 15754315.

17. Huang WY, Olshan AF, Schwartz SM, Berndt SI, Chen C, Llaca V, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XR CC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2005; 7. 14(7):1747–1753. PMID: 16030112.

18. Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 2001; 2. 15. 61(4):1354–1357. PMID: 11245433.

19. Liang G, Xing D, Miao X, Tan W, Yu C, Lu W, et al. Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population. Int J Cancer. 2003; 7. 10. 105(5):669–673. PMID: 12740916.

20. Chen S, Tang D, Xue K, Xu L, Ma G, Hsu Y, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis. 2002; 8. 23(8):1321–1325. PMID: 12151350.

21. Park JY, Lee SY, Jeon HS, Park SH, Bae NC, Lee EB, et al. Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer. 2002; 4. 36(1):15–16. PMID: 11891028.

22. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer. 2004; 6. 44(3):311–316. PMID: 15140544.

23. Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem. 1997; 9. 19. 272(38):23465–23468. PMID: 9295277.

24. Qiao Y, Spitz MR, Shen H, Guo Z, Shete S, Hedayati M, et al. Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis. 2002; 2. 23(2):295–299. PMID: 11872635.

25. Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, Wain JC, et al. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res. 2002; 3. 01. 62(5):1377–1381. PMID: 11888908.

26. Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRC C3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003; 3. 10. 191(2):171–178. PMID: 12618330.

27. Benhamou S, Sarasin A. ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol. 2005; 1. 01. 161(1):1–14. PMID: 15615908.

28. Hamajima N, Saito T, Matsuo K, Suzuki T, Nakamura T, Matsuura A, et al. Genotype frequencies of 50 polymorphisms for 241 Japanese non-cancer patients. J Epidemiol. 2002; 5. 12(3):229–236. PMID: 12164325.